Phase 3 Leukaemia Trial, Recruiting NCT07503730 Sponsor: First Affiliated Hospital Xi'an Jiaotong University Condition: Leukaemia
Back to Leukaemia

Phase 3 Leukaemia Trial, Recruiting

NCT07503730
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years old
  • People who have been diagnosed with a type of blood cancer called acute myeloid leukemia, confirmed through bone marrow testing, and where doctors strongly suspect a specific subtype called acute promyelocytic leukemia (APL)

Who may not be able to join:

  • People whose testing (including chromosome analysis and a specific gene test) has confirmed that their leukemia is not the APL subtype — meaning the PML-RARα gene change was not found
  • People with serious liver or kidney problems that are not caused by the leukemia itself — for example, certain blood markers for liver or kidney function being well above the normal range (confirm with trial site for specific thresholds)
  • People with serious heart problems, such as reduced heart pumping function below a certain level (confirm with trial site)
  • People who have another type of cancer at the same time
  • Women who are pregnant or currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +8618991232410

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
1 June 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Early Death Rate; Early death rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov